Repetitive Transcranial Magnetic Stimulation for "Voices"

NCT ID: NCT00004980

Last Updated: 2013-08-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

1999-12-31

Study Completion Date

2005-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

OBJECTIVES:

I. Determine the effect of repetitive transcranial magnetic stimulation on treatment refractory auditory hallucinations of patients with schizophrenia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PROTOCOL OUTLINE: This is a randomized, double blind study. Patients are randomized to one of two treatment arms.

Group I: Patients receive 9 sessions of active transcranial magnetic stimulation (rTMS) which consists of 8 minutes of rTMS during session 1, 12 minutes duration during session 2, and 16 minutes duration during sessions 3-9. The total duration of stimulation is 132 minutes. Each session was given on a separate day and in general each session occurred on consecutive days with the exception of weekends.

Group II: Patients receive 9 sessions of sham stimulation, which consists of 8 minutes of sham stimulation during session 1, 12 minutes duration sham stimulation during session 2, and 16 minutes duration sham stimulation during sessions 3-9. The total duration of sham stimulation is 132 minutes. Each session was given conducted on a separate day and in general each session occured on consecutive days with the exception of weekends.

This study provided pilot data supplying the basis for our current study - NCT00308997 -- see our website for details

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

neurologic and psychiatric disorders rare disease schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

active rTMS

1-Hz rTMS delivered to left temporoparietal cortex at 90% motor threshold for 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)

Group Type EXPERIMENTAL

repetitive transcranial magnetic stimulation (rTMS)

Intervention Type DEVICE

a total of 132 minutes of stimulation at one hertz, motor threshold set at 80%, delivered to TP3 scalp site

sham stimulation

Sham stimulation delivered 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)

Group Type PLACEBO_COMPARATOR

sham stimulation

Intervention Type DEVICE

132 minutes of stimulation given at 80% motor threshold with coil tilted "single wing" 45 degrees away from scalp deliverd to TP3 site

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

repetitive transcranial magnetic stimulation (rTMS)

a total of 132 minutes of stimulation at one hertz, motor threshold set at 80%, delivered to TP3 scalp site

Intervention Type DEVICE

sham stimulation

132 minutes of stimulation given at 80% motor threshold with coil tilted "single wing" 45 degrees away from scalp deliverd to TP3 site

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MATSTIM SUPER RAPID MAGSTIM SUPER RAPID

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of schizophrenia or schizoaffective disorder based on DSM-IV version of SCID
* Auditory hallucinations of spoken speech occurring at least 5 times per day where subject able to discern verbal content
* Right-handed
* At least 4 weeks on stable antipsychotic medication

Exclusion Criteria

* history of seizure (unless due to drug withdrawal or medication that is no longer prescribed)
* history of epilepsy in first degree relatives
* estimated IQ less than 80
* unable to provide informed consent
* significant unstable medical condition
* current treatment with clozapine or bupropion
* cochlear implants or other metal in the head (surgical, etc.)
* history of cardiac arrhythmia
* cardiac pacemaker
* active drug or alcohol abuse within prior 6 weeks
* pregnancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Mental Health (NIMH)

NIH

Sponsor Role collaborator

Yale University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ralph Hoffman

Role: STUDY_CHAIR

Yale University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yale University School of Medicine

New Haven, Connecticut, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Hoffman RE, Gueorguieva R, Hawkins KA, Varanko M, Boutros NN, Wu YT, Carroll K, Krystal JH. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biol Psychiatry. 2005 Jul 15;58(2):97-104. doi: 10.1016/j.biopsych.2005.03.041.

Reference Type RESULT
PMID: 15936729 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R21MH063326

Identifier Type: NIH

Identifier Source: secondary_id

View Link

YALESM-9281

Identifier Type: -

Identifier Source: secondary_id

199/14809

Identifier Type: -

Identifier Source: secondary_id

A5-ETPD

Identifier Type: -

Identifier Source: secondary_id

R21MH063326

Identifier Type: NIH

Identifier Source: org_study_id

View Link